China SXT Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
China SXT Pharmaceuticals's earnings have been declining at an average annual rate of -18.2%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been declining at an average rate of 30% per year.
Key information
-18.2%
Earnings growth rate
33.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | -30.0% |
| Return on equity | -22.2% |
| Net Margin | -160.7% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How China SXT Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 2 | -3 | 3 | 0 |
| 31 Dec 23 | 2 | -9 | 8 | 0 |
| 30 Sep 23 | 2 | -14 | 14 | 0 |
| 30 Jun 23 | 2 | -10 | 10 | 0 |
| 31 Mar 23 | 2 | -6 | 6 | 0 |
| 31 Dec 22 | 2 | -5 | 5 | 0 |
| 30 Sep 22 | 3 | -4 | 4 | 0 |
| 30 Jun 22 | 3 | -5 | 5 | 0 |
| 31 Mar 22 | 3 | -6 | 6 | 0 |
| 31 Dec 21 | 2 | -6 | 7 | 0 |
| 30 Sep 21 | 2 | -7 | 7 | 0 |
| 30 Jun 21 | 3 | -5 | 6 | 0 |
| 31 Mar 21 | 5 | -3 | 5 | 0 |
| 31 Dec 20 | 5 | -5 | 4 | 0 |
| 30 Sep 20 | 6 | -7 | 4 | 0 |
| 30 Jun 20 | 5 | -8 | 4 | 0 |
| 31 Mar 20 | 5 | -10 | 4 | 0 |
| 31 Dec 19 | 6 | -6 | 4 | 0 |
| 30 Sep 19 | 6 | -2 | 4 | 0 |
| 30 Jun 19 | 7 | 0 | 3 | 0 |
| 31 Mar 19 | 7 | 2 | 3 | 0 |
| 31 Dec 18 | 7 | 1 | 3 | 0 |
| 30 Sep 18 | 7 | 1 | 3 | 0 |
| 30 Jun 18 | 7 | 1 | 2 | 0 |
| 31 Mar 18 | 7 | 1 | 2 | 0 |
| 31 Dec 17 | 7 | 1 | 1 | 0 |
| 31 Mar 17 | 5 | 1 | 1 | 0 |
| 31 Mar 16 | 4 | 0 | 1 | 0 |
Quality Earnings: 2RY0 is currently unprofitable.
Growing Profit Margin: 2RY0 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2RY0 is unprofitable, and losses have increased over the past 5 years at a rate of 18.2% per year.
Accelerating Growth: Unable to compare 2RY0's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2RY0 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.7%).
Return on Equity
High ROE: 2RY0 has a negative Return on Equity (-22.24%), as it is currently unprofitable.